3T Biosciences secures $40 million in Series A financing

3T Biosciences is an immunotherapy developer with the 3T-TRACE platform, which combines a highly diverse target library with AI machine learning technology to identify novel targets and TCRs. This platform can identify tumor-specific anti-tumor immune responses from patient samples and discover the most prevalent and immunogenic targets in solid tumors. 3T Biosciences announced that it has raised $40 million in Series A financing, led by Westlake Village BioPartners and joined by Lightspeed Venture Partners.

This article is reproduced from: https://www.itjuzi.com/investevent/13512540
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment